Compare AP & BDTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AP | BDTX |
|---|---|---|
| Founded | 1929 | 2014 |
| Country | United States | United States |
| Employees | 1432 | N/A |
| Industry | Fluid Controls | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 212.2M | 171.9M |
| IPO Year | N/A | 2020 |
| Metric | AP | BDTX |
|---|---|---|
| Price | $11.83 | $1.76 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $9.67 |
| AVG Volume (30 Days) | 131.9K | ★ 2.1M |
| Earning Date | 05-12-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 130.71 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.75 | $1.78 |
| 52 Week High | $12.30 | $4.94 |
| Indicator | AP | BDTX |
|---|---|---|
| Relative Strength Index (RSI) | 58.49 | 33.02 |
| Support Level | $8.95 | N/A |
| Resistance Level | N/A | $2.30 |
| Average True Range (ATR) | 0.86 | 0.14 |
| MACD | -0.00 | -0.06 |
| Stochastic Oscillator | 90.58 | 5.41 |
Ampco-Pittsburgh Corp manufactures and sells engineered, high-performance specialty metal products and customized equipment utilized by industry throughout the world. It operates in two business segments, namely the Forged and Cast Engineered Products segment and the Air and Liquid Processing segment. The Forged and Cast Engineered Products segment produces forged hardened steel rolls, cast rolls, and open-die forged products. Forged hardened steel rolls are used in cold rolling mills by producers of steel, aluminum, & other metals. The Air and Liquid Processing segment includes Aerofin, Buffalo Air Handling, & Buffalo Pumps. The company generates a majority of its revenue from the Forged & Cast Engineered Products segment. It has a business presence in the United States & other countries.
Black Diamond Therapeutics Inc is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. The foundation of companies has been built upon a deep understanding of cancer genetics, onco-protein structure and function, and medicinal chemistry. Its clinical-stage program, silevertinib (formerly BDTX-1535), a brain-penetrant, fourth-generation epidermal growth factor receptor (EGFR) MasterKey inhibitor, is currently being studied in a Phase 2 clinical trial in patients with epidermal growth factor receptor mutant (EGFRm) non-small cell lung cancer (NSCLC). The Company manages its operations as a single operating segment and single reportable segment.